ArticleFrontiers in pharmacology2026
DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effects
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to develop DABPU-DM derivatives that inhibit host adipose triglyceride lipase (ATGL) and identify the one with the highest broad-spectrum anti-coronaviral efficacy. Methods: The antiviral effectiveness of DABPU-DM derivatives against representative viruses from all four genera within the subfamily Results: Among six ATGL inhibitors, DABPU-DE exhibited the highest antiviral activity and safety, yielding a more favorable selectivity index than the other compounds. The enhanced antiviral effectiveness of DABPU-DE was linked to its diethylurea group, which increases ATGL binding affinity by enhancing hydrophobic and hydrogen-bonding interactions. In contrast, the weakest antiviral effect was observed with DABPU-DPh because its bulky diphenylurea group sterically hindered optimal binding and reduced interactions with ATGL. Additionally, combining DABPU-DE with remdesivir, which targets viral RNA-dependent RNA polymerase, produced strong, synergistic suppression of SARS-CoV-2 infection in Vero E6 cells. Conclusion: Our findings indicate that the broad-spectrum anti-coronaviral activity of these compounds, particularly DABPU-DE, provides a promising preclinical foundation. This study underscores the potential of ATGL-targeted interventions as a viable strategy for managing current SARS-CoV-2 variants and preparing for future coronavirus outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.